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Intracellular	delivery	of	a	catalytic	organometallic	complex	
Eugenio	Indrigo,†	Jessica	Clavadetscher,†	Sunay	V.	Chankeshwara,	Alicia	Megia-Fernandez,	
Annamaria	Lilienkampf	and	Mark	Bradley*a	
A	homogeneous	carbene-based	palladium	catalyst	was	conjugated	
to	 a	 cell-penetrating	 peptide,	 allowing	 intracellular	 delivery	 of	
catalytically	 active	 Pd	 complexes	 that	 demonstrated	
bioorthogonal	 activation	 of	 a	 profluorophore	 within	 prostate	
cancer	cells.	
In	 recent	 years,	 bioorthogonal	 organometallic	 reactions	 have	
been	successfully	applied	 in	chemical	biology.1–8	 In	particular,	
Pd-mediated	 chemical	 transformations	 have	 been	 used	 to	
modify	or	synthesise	molecules	through	cleavage	of	protecting	
groups	 or	 cross-coupling	 reactions.5,9	 The	 first	 use	 of	 Pd	
chemistry	in	mammalian	cells	was	reported	by	Bradley,10	who	
trapped	Pd	nanoparticles	within	an	inert	polymer	microsphere	
for	 intracellular	 delivery.	 This	 “active”	 transition	 metal	 was	
used	 to	 mediate	 C–C	 bond	 formation	 via	 a	 Suzuki–Miyaura	
cross-coupling	 and	 allyl	 carbamate	 cleavage	 reactions	 inside	
living	cells,	including	the	intracellular	activation	of	a	prodrug	of	
the	 antineoplastic	 agent	 amsacrine.	 This	 approach	 was	 also	
used	 to	 convert	 propargyl	 derivatives	 of	 5-fluorouracil	 and	
gemcitabine	 to	 their	 active	 forms,	 as	well	 as	 catalyse	 Suzuki-
Miyaura	 cross-couplings	 of	 drugs	 in	 the	 presence	 of	 an	
extracellular	 heterogeneous	 Pd	 catalyst.11–13	 Pd-mediated	
transformations	 have	 since	 also	 been	 used	 to	 selectively	
activate	 biomolecules	 in	 cells.	 Chen	 developed	 the	 chemical	
activation	 of	 proteins	 based	 on	 the	 decaging	 of	
propargylcarbamate	 caged	 lysine	 with	 simple	 Pd	 salts,	 while	
Pd(NO3)2,	 Pd(dba)2,	 and	 allyl2PdCl2,	 have	 also	 been	 used	 to	
mediate	 Sonogashira	 cross-coupling	 reactions	 inside	
bacteria,14	or	 to	activate	a	protein	of	 interest	 inside	cells.14–17	
However,	under	optimised	conditions,	50	equivalents	of	these	
Pd	 complexes	 are	 required	 for	 the	 completion	 of	 the	 cross-
coupling	 reactions.16	 The	 major	 drawbacks	 of	 all	 the	 above	
methods	are	the	lack	of	cell	selectivity	of	the	catalyst	and	the	
use	 of	 stoichiometric,	 or	 even	 excess	 (up	 to	 500	 eq.),	 Pd	
complex	 and	 the	 cellular	 toxicity	 when	 used	 in	 non-
complexed/encapsulated	form.5,18	Targeted	localisation	of	a	Pd	
catalyst,	by	means	of	cell	selective	delivery	of	a	homogeneous	
catalyst,	would	represent	a	major	advance	in	the	field.	
Herein,	we	have	extended	the	scope	of	Pd	catalysed	chemistry	
in	 living	systems	by	developing	a	method	to	deliver	and	track	
an	 active	 organometallic	 complex	 inside	 mammalian	 cells.	
These	water-soluble	 and	 traceable	 catalysts	were	based	on	 a	
Pd(II)–carbene	 complex	 coupled	 to	 a	 fluorescently	 labelled	
homing	 peptide	 for	 targeted	 cell	 delivery.	 The	 biocompatible	
homogeneous	Pd	catalyst	was	based	on	a	previously	reported	
carbene	 Pd	 ligand	 coupled	 to	 a	 peptide.19,20	 N-heterocyclic	
carbenes	 (NHC)	 are	 strong	 σ-electron	 donating	 molecules	
(enhancing	the	rate	of	oxidative	addition),	coordinate	tightly	to	
Pd	 centres	 (disfavouring	 aggregation),	 and	 can	 have	 bulky	
substituents	(increasing	the	rate	of	reductive	elimination).21,22	
Peptides	were	chosen	to	deliver	the	Pd	complex	inside	cells	as	
they	 are	 biocompatible,	 easy	 to	 prepare	 by	 solid-phase	
peptide	 synthesis	 (SPPS),	 versatile,	 readily	 labelled	 and	
functionalised,	with	known	cell	delivery	abilities.23	
	
Scheme	1:	Synthetic	route	to	the	Pd–peptide	catalysts	on	a	Rink	 functionalised	
polystyrene	resin.		
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Fig.	1.	Cellular	uptake	of	Pd–peptide	2.	(A)	Structure	of	the	carboxyfluorescein	labelled	Pd–peptide	2.	(B)	Intracellular	Pd	content	(ng	Pd	per	million	cells)	of	PC-3	cells	
incubated	with	10	µM	Pd(OAc)2	or	2	(3	µM	and	30	µM)	for	2	h	(higher	concentrations	of	Pd(OAc)2	were	toxic).	Cells	were	harvested,	lysed	and	the	cell	content	was	
subjected	to	ICP-OES	measurements.	(C)	Flow	cytometry	histograms	showing	the	uptake	of	2	(30	µM)	in	PC-3	cells	after	2	h	(in	black)	and	untreated	control	cells	(in	
grey).	(D)	PC-3	cells	were	incubated	with	2	(30	µM)	for	2	h,	fixed	with	4	%	paraformaldehyde,	stained	with	DAPI	(nuclei	stain)	and	imaged	by	confocal	microscopy.	
Panels	 show	 (i)	 Pd	 catalyst	2	 (green,	 λex	 =	 488	nm)	 located	 in	 the	 cytoplasm	and	nucleus,	 (ii)	 cell	 nucleus	 (blue,	 λex	 =	 405	nm),	 and	 (iii)	merged	 image	 (light	blue	
indicates	co-localisation).	Scale	bar	20	µm.	
The	polycationic	(tri-lysine)	catalyst	1	represented	a	simple	cell	
penetrating	 peptide	 (CPP)	 which	 was	 able	 to	 cross	 the	 cell	
membrane,23	and	could	be	readily	labelled	to	allow	tracking	of	
the	catalyst	inside	cells.		
Here,	 either	 5(6)-carboxyfluorescein	 (FAM,	 λEx/Em	 =	 492/517	
nm)	or	sulfonated	Cy5	(λEx/Em	=	630/654	nm)	were	attached	to	
the	 peptides	 to	 give	 the	 fluorescent	 Pd-catalysts	 2	 and	 3,	
respectively	(Scheme	1).	Peptides	1,	2	and	3	were	synthesised	
on	a	Rink	amide	linker	functionalised	aminomethyl	polystyrene	
resin	 using	 standard	 Fmoc/tBu	 SPPS	 with	 Oxyma/DIC	 as	 the	
coupling	 combination	 (Scheme	 1	 and	 ESI).	 Coupling	 of	 the	
fluorophores	 in	2	 and	3	was	achieved	by	 introducing	a	bis-N-
[1-(4,4-dimethyl-2,6-dioxocyclo	 hexylidene)	 ethyl]	 (Dde)	
protected	Lys	as	the	first	amino	acid	(Fmoc-Lys(Dde)-OH).	Prior	
to	 Fmoc	 removal	 of	 the	 terminal	 Lys	 residue,	 the	 Dde	 group	
was	 orthogonally	 removed	 with	 hydroxylamine24	 and	 the	
liberated	 amine	 coupled	 to	 the	 activated	 dye.	 The	 imidazole	
ligand	4	 was	 coupled	 to	 the	 amino	 terminus	 of	 the	 peptides	
using	 TBTU	 as	 an	 activating	 agent.	 The	 imidazole	 salt	 was	
treated	with	 the	base	BEMP	 to	 form	 the	 carbene,	which	was	
subsequently	 trapped	 by	 the	 addition	 of	 dichloro(1,5-
cyclooctadiene)	palladium(II)	(PdCl2COD)	as	the	source	of	Pd.
19	
The	 catalysts	were	 cleaved	 from	 the	 resin	 by	 treatment	with	
TFA	 (5	 %	 water,	 addition	 of	 conventional	 scavenging	 agents	
destroyed	 the	Pd	complex)	and	purified	by	preparative	HPLC.	
To	 evaluate	 the	 catalytic	 activity	 in	 a	 biological	 setting,	 non-
fluorescent	bis-propargyloxycarbonyl	(Proc)	rhodamine	110	(5)	
was	 treated	 with	 Pd	 catalyst	 1	 in	 phosphate	 buffered	 saline	
(PBS)	and	PC-3	(prostate	adenocarcinoma)	cell	lysate	(see	ESI).	
Upon	Pd	catalysed	cleavage	of	the	protecting	groups	with	0.1	
eq	of	1	for	24	h,	fluorescent	6	was	generated	giving	a	200-fold	
increase	in	fluorescence.	The	reaction	in	cell	lysate	resulted	in	
a	more	modest	9-fold	relative	increase	in	fluorescence	with	0.1	
eq	 of	 the	 catalyst,	 but	 demonstrated	 that	 the	 Pd–peptide	
hybrid	was	 catalytically	 competent	 even	 in	 the	presence	of	 a	
complex	mixture	of	biomolecules.		
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Fig.	2.	Pd	catalysed	decaging	of	proc-rhodamine	5	 in	PC-3	cells.	(A)	Catalysed	fluorescence	“switch-on”	of	the	caged	fluorophore	5	with	the	Pd–peptide	complex	3.		
Cells	were	incubated	with	Pd–peptide	3	(30	µM)	for	2	h,	followed	by	incubation	with	5	(50	µM)	for	18	h.	(B)	Confocal	microscopy	images	of	PC-3	cells	fixed	with	4	%	
paraformaldehyde	and	stained	with	DAPI	(nuclei	stain).	Panels	show:	(i)	cell	nucleus	(blue,	λex	=	405	nm)	and	Pd-peptide	3	(magenta,	λex	=	633	nm),	(ii)	cell	nucleus	
(blue)	and	in	situ	synthesised	6	(green,	λex	=	488	nm),	and	(iii)	merged	image.	Scale	bar	20	µm.	(C)	Flow	cytometry	cytograms	showing:	(i)	untreated	control	cells,	(ii)	
cells	treated	with	proc-rhodamine	5,	and	(iii)	cells	treated	with	5	and	3.	
The	 cellular	 uptake	 of	 the	 carboxyfluorescein	 labelled	 Pd–
peptide	 2	 was	 investigated	 with	 the	 total	 quantity	 of	 the	
internalised	 Pd	 determined	 by	 inductively	 coupled	 plasma	
optical	 emission	 spectrometry	 (ICP-OES)	 analysis	of	PC-3	 cells	
(Fig.	 1b),	 giving	 a	 total	 Pd	 content	 of	 20	 ng	 per	million	 cells	
(when	 incubated	with	 30	µM	of	2	 for	 2	 h),	 showing	 a	 higher	
metal	 uptake	 compared	 to	 cells	 treated	 with	 10	 µM	 of	
Pd(OAc)2	 (higher	 concentration	 of	 Pd(OAc)2	 showed	
cytotoxicity).	 Catalyst	 2	 showed	 no	 cytotoxicity	 even	 at	 200	
µM	 (see	ESI).	 The	cellular	uptake	and	 intracellular	 location	of	
the	 Pd	 catalyst	 2	 was	 investigated	 by	 flow	 cytometry	 and	
confocal	microscopy	 (Figure	 1c	 and	 1d).	 PC-3	 cells	 showed	 a	
shift	of	the	whole	cell	population	towards	higher	fluorescence	
intensity	after	2	h	incubation	with	catalyst	2	(30	µM),	with	the	
fluorescence	localised	within	the	cytoplasm	and,	unexpectedly,	
in	 the	 nucleus	 (cationic	 peptides	 generally	 localise	 in	 the	
cytoplasm	and	in	vesicles25,26).		
The	catalytic	activity	of	 the	Pd–peptide	catalysts	 in	cell-based	
assays	via	 proc-rhodamine	5	 activation	was	 investigated	with	
the	Cy5	labelled	Pd–peptide	3.	PC-3	cells	were	incubated	with	
3	(30	µM)	for	2	h,	washed	to	remove	any	extracellular	catalyst,	
and	 subsequently	 incubated	with	 5	 (50	 µM)	 for	 18	 h	 (Figure	
2a).	Fluorescence	microscopy	verified	the	presence	of	the	Pd-
catalyst	3	as	well	as	synthesised	6	within	the	cytoplasm	of	PC-3	
cells	(Fig.	2b).	Analysis	by	flow	cytometry	showed	a	shift	of	the	
whole	cell	population	towards	higher	fluorescence	intensity	in	
the	Cy5	channel	 indicating	 the	uptake	of	 the	catalyst,	while	a	
shift	to	higher	FITC	intensity	indicated	the	formation	of	6	(Fig.	
2c).		
In	conclusion,	we	have	demonstrated	the	ability	to	combine	a	
catalytically	 active	 Pd	 complex	 with	 a	 cell-delivery	 peptide	
scaffold,	 which	 was	 able	 to	 catalyse	 a	 depropargylation	
reaction	in	a	biologically	relevant	setting.	The	non-cytotoxic	Pd	
catalyst	 was	 successfully	 used	 in	 the	 fluorescent	 labelling	 of	
mammalian	 cells,	 showing	 significant	 catalytic	 activity	 in	 an	
intracellular	environment.	Future	applications	will	thus	include	
the	activation	of	prodrugs	via	these	Pd	catalysts.	This	new	type	
of	 catalytic	 system	 gives	 the	 basis	 for	 a	 wide	 range	 of	
biocompatible	catalysts,	where	their	facile	modification	allows	
the	 incorporation	 of	 a	 variety	 of	 different	 targeting	 peptides	
that	could	selectively	enter	different	cells	or	specific	tissues.			
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